Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Michael PennickBiosciences Department, Shire Pharmaceutical Development Ltd, Basingstoke, UKAbstract: These studies investigated the absorption and metabolic conversion of lisdexamfetamine dimesylate (LDX), a prodrug stimulant that requires conversion to d-amphetamine for activity. Oral absorption o...
Guardado en:
Autor principal: | Michael Pennick |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/50dcc49742e546ef94b5dfbec870a8c2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Physician perception of clinical improvement in children with attention-deficit/hyperactivity disorder: a post hoc comparison of lisdexamfetamine dimesylate and mixed amphetamine salts extended release in a crossover analog classroom study
por: López F, et al.
Publicado: (2011) -
Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults
por: Ermer J, et al.
Publicado: (2013) -
Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells
por: Sharman J, et al.
Publicado: (2014) -
Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial
por: Coghill DR, et al.
Publicado: (2014) -
Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylate
por: Weisler RH, et al.
Publicado: (2013)